title: Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285).
abstract: OBJECTIVE
  To compare the efficacy and the toxicity of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer.
  
  
  METHODS
  A total of 94 patients with no prior chemotherapy and measurable metastatic large bowel cancer were randomly assigned to one of the two treatment regimens. Eastern Cooperative Oncology Group (ECOG) criteria were used to evaluate response and toxicity.
  
  
  RESULTS
  Fifty patients were randomized to PF and 44 to MVPF. Toxicity was evaluable in all patients except one; response was evaluable in 40 and 31, with response rate of 13 and 42%, respectively. Intent-to-treat analysis showed a response rate of 12 and 32%, respectively (p = 0.076), where it was assumed that none of the ineligible or unevaluable patients responded. Median survival for all patients was 9 months, with no difference between PF and MVPF. ECOG Performance Status (0 vs. 1), weight loss (< or =10 vs. >10%) and site of metastatic lesion had statistically significant impact on survival. MVPF was definitely more toxic than PF (p < 0.000005).
  
  
  CONCLUSIONS
  Both treatment regimens showed clinical activity. The MVPF regimen resulted in more responses than PF, no improvement in survival, and more toxicity.
authors.affiliation: University of Rochester Cancer Center, Rochester, NY 14642, USA. Kishan_Pandya@urmc.rochester.edu
authors.forename: Kishan J
authors.initials: KJ
authors.lastname: Pandya
authors.forename: Myrto
authors.initials: M
authors.lastname: Lefkopoulou
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Petrelli
authors.forename: David J
authors.initials: DJ
authors.lastname: Vaughn
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Smith
authors.forename: Jules E
authors.initials: JE
authors.lastname: Harris
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Haller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D016016:Proportional Hazards Models; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D016685:Mitomycin; D014750:Vincristine; D014747:Vinblastine; D002945:Cisplatin; D005472:Fluorouracil